FDA-approved1,2Evidence: Limited human dataNot a peptideMetabolic and weight

Metreleptin1,2

Also called Myalept1

Not a peptide: a protein, larger than a peptide, often looked up alongside peptides.

Key takeaway

Metreleptin is a lab-made form of the fat-cell hormone leptin, with one extra amino acid, and the active ingredient in Myalept. At 147 amino acids it is a protein under FDA’s definition, not a peptide.1,3 FDA approved Myalept in 2014 to treat the complications of leptin deficiency in people with congenital or acquired generalized lipodystrophy, a lack of body fat tissue, alongside diet.1,2 Its label carries a boxed warning about antibodies that can neutralize leptin and about T-cell lymphoma, and it is available only through a restricted program.1

Metreleptin at a glance

Substance typeNot a peptide. The Myalept label states that metreleptin is 147 amino acids long, and FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids.1,3
What it isRecombinant methionyl-human leptin: human leptin with an added methionine at its start, 147 amino acids long, made in E. coli, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Myalept, application 125390, with an original approval date of February 24, 2014. The label has a boxed warning about neutralizing antibodies and lymphoma.1,2
Human evidenceAn open-label, single-arm study in 48 people with generalized lipodystrophy, described in the label.1
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is metreleptin?

Metreleptin is a recombinant analogue of human leptin made in E. coli. The label states that it differs from natural leptin by one added methionine and is a nonglycosylated chain of 147 amino acids.1

FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids, so metreleptin counts as a protein, not a peptide.1,3

In the United States it is the active ingredient of Myalept, approved under application 125390, according to Drugs@FDA.2

How does metreleptin work?

Leptin is a hormone made mainly by fat tissue that tells the brain about the body’s energy stores. In generalized lipodystrophy, a lack of fat tissue leads to very low leptin, high triglycerides and fat build-up in the liver and muscle, according to the label.1

Metreleptin binds to and activates the leptin receptor, replacing the missing hormone, according to the label.1

What do human studies show?

The label describes an open-label, single-arm study in 48 people with generalized lipodystrophy and diabetes, high triglycerides or high fasting insulin; most were under 18.1

At one year, mean HbA1c fell by 2 percentage points, mean fasting glucose also fell, and median fasting triglycerides fell by 55%. The label notes that other diabetes and lipid medicines were not held constant during the study.1

What the evidence base contains

  • Small, short, or incompletely reported human study An open-label, single-arm study in 48 people with congenital or acquired generalized lipodystrophy, in which mean HbA1c fell by 2 percentage points and median fasting triglycerides by 55% at one year, described in the label.1

Evidence-strength label: Limited human data. How this label is assigned

Is metreleptin FDA-approved?

Yes. Drugs@FDA lists Myalept, application 125390, with an original approval date of February 24, 2014.2

The Myalept label cited here (DailyMed SPL version 18, published March 10, 2025) states that it is indicated, as an adjunct to diet, as replacement therapy for the complications of leptin deficiency in people with congenital or acquired generalized lipodystrophy, and that it is not established for partial lipodystrophy, liver disease or HIV-related lipodystrophy.1

The label carries a boxed warning that antibodies that neutralize leptin have developed in treated patients, with possible loss of effect and severe infections, and that T-cell lymphoma has been reported in people with acquired generalized lipodystrophy, whether or not they were treated. It is available only through a restricted program, the Myalept REMS.1

Timeline

  1. FDA approves Myalept, application 125390, according to Drugs@FDA.2
  2. DailyMed publishes version 18 of the Myalept label, the version cited here.1

What is still unknown?

How much of the improvement is due to metreleptin itself, since the main study had no comparison group and other medicines changed during it.1

The long-term consequences of the neutralizing antibodies, which the label states are not well characterized.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Metreleptin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Metreleptin are a bounded selection, not every registration or paper about Metreleptin. For the years before Metreleptin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Metreleptin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Metreleptin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Myalept for generalized lipodystrophy. Approval rests on an open-label, single-arm study in 48 people. The label carries a boxed warning about neutralizing antibodies and lymphoma.↗↗

Status sources checked through November 16, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Metreleptin?

FDA-approved as Myalept for generalized lipodystrophy. Approval rests on an open-label, single-arm study in 48 people. The label carries a boxed warning about neutralizing antibodies and lymphoma.↗↗

The cited status sources were checked through November 16, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
14
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Metreleptin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

43Selected dated records
46Connected citations
14Populated source years2013–2026
3/4Record lanes present

Registered human studies

Trial composition

24 of 25 selected trial records include at least one phase value; 25 of 25 include a status value in the retained structured contract.

PhasesPhase 2 18Phase 3 3Phase 1 2Phase 4 2Not applicable 1
Status at observationCompleted 17Active, not recruiting 4Recruiting 4

A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”

PubMed bibliography

Publication composition

15 of 15 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 13Case Reports 6Review 4Comment 1Controlled Clinical Trial 1Editorial 1Letter 1Research Support, N.I.H., Intramural 1Research Support, Non-U.S. Gov't 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
2
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
43

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 43 dated records

Research hub

Explore the Metreleptin evidence record

Open all 43 records →
43Dated records
3Evidence types
43Cited public sources
14Source years

Change ledger

Recently changed for Metreleptin

Open all 43 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

Federal Register notice 2013-25588

The Federal Register published notice 2013-25588, attributed to FDA and its parent HHS department, on 2013-10-30. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.

PeptideScanner change date
November 17, 2026
Cited source date
October 30, 2013
Evidence lane
Regulatory
Record added

Federal Register notice 2016-22935

The Federal Register published notice 2016-22935, attributed to FDA and its parent HHS department, on 2016-09-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.

PeptideScanner change date
November 17, 2026
Cited source date
September 23, 2016
Evidence lane
Regulatory

Official-source collections

Source records for Metreleptin

Open the full research atlas →
PubMed15

15 with attributed title, venue, publication-date, and type metadata.

  1. Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date.Frontiers in endocrinology · 2026 05 13
  2. Metreleptin In SHORT Syndrome With Uncontrolled Diabetes.JCEM case reports · 2025 10 09
  3. Long-Term Clinical Experience With Metreleptin in a Brazilian Patient With Congenital Generalized Lipodystrophy Type 2.JCEM case reports · 2025 08 22
Explore all selected literature →
ClinicalTrials.gov25

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT02262806Registry update November 9, 2026 · current at observation
  2. NCT05164341Registry update November 9, 2026 · completed at observation
  3. NCT02262832Registry update October 27, 2026 · current at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span October 30, 2013 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2,3
Dated updates connected to this profile · 43

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT02262806↗

    PeptideScanner retained ClinicalTrials.gov record NCT02262806 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05164341↗

    PeptideScanner retained ClinicalTrials.gov record NCT05164341 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  3. Literature metadata

    Metreleptin treatment of non-HIV lipodystrophy syndromes.↗

    PubMed lists PMID 34571177 in Presse medicale (Paris, France : 1983) as Journal Article, Review, with publication-date metadata of 2021-09-24 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT02262832↗

    PeptideScanner retained ClinicalTrials.gov record NCT02262832 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  5. Literature metadata

    Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date.↗

    PubMed lists PMID 42222073 in Frontiers in endocrinology as Case Reports, Journal Article, with publication-date metadata of 2026-05-13 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT06305182↗

    PeptideScanner retained ClinicalTrials.gov record NCT06305182 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT02325674↗

    PeptideScanner retained ClinicalTrials.gov record NCT02325674 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT06679270↗

    PeptideScanner retained ClinicalTrials.gov record NCT06679270 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  9. Literature metadata

    First metreleptin treatment for generalized lipodystrophy in Turkey.↗

    PubMed lists PMID 27717125 in Diabetes, obesity & metabolism as Case Reports, Letter, with publication-date metadata of 2016-11-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT04026178↗

    PeptideScanner retained ClinicalTrials.gov record NCT04026178 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-11-26, and PeptideScanner's reviewed identity mapping was metreleptin.↗

  11. Literature metadata

    Metreleptin In SHORT Syndrome With Uncontrolled Diabetes.↗

    PubMed lists PMID 41080980 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-10-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Long-Term Clinical Experience With Metreleptin in a Brazilian Patient With Congenital Generalized Lipodystrophy Type 2.↗

    PubMed lists PMID 40860570 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    MYALEPT (metreleptin) for injection · SPL version 18 · published 2025-03-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  2. 2
    Drugs@FDA: MYALEPT (metreleptin), application 125390 · original approval February 24, 2014 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  3. 3
    Definition of the Term “Biological Product” (final rule, February 21, 2020) · FR Doc. 2020-03505 ↗

    Federal Register · Official source · Source checked November 16, 2026